In aggressive variants of non-Hodgkin lymphomas, Ezh2 is strongly expressed and polycomb repressive complex PRC1.4 dominates over PRC1.2

Virchows Archiv

Volumn 463, Issue 5, 2013, Pages 697-711

  Abd Al Kader, Lamia ^a,e   Oka, Takashi ^a   Takata, Katsuyoshi ^a   Sun, Xu ^f   Sato, Hiaki ^b   Murakami, Ichiro ^a,c   Toji, Tomohiro ^a   Manabe, Akihiro ^a   Kimura, Hiroshi ^d   Yoshino, Tadashi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

^c TOTTORI UNIVERSITY   (Japan)

^d OSAKA UNIVERSITY   (Japan)

^e MANSOURA UNIVERSITY   (Egypt)

^f DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

Bmi 1; Ezh2; Malignant lymphoma; Mel 18; PRC1.2; PRC1.4

Indexed keywords

BMI1 PROTEIN; KI 67 ANTIGEN; POLYCOMB GROUP PROTEIN; PROTEIN MEL 18; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG;

ARTICLE; B LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; HEMATOPOIESIS; HODGKIN DISEASE; HUMAN; HUMAN CELL; LYMPHOID TISSUE; LYMPHOMA CELL LINE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR; T CELL LYMPHOMA; TUMOR CELL;

CELL CYCLE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, B-CELL; LYMPHOMA, NON-HODGKIN; POLYCOMB REPRESSIVE COMPLEX 1; POLYCOMB REPRESSIVE COMPLEX 2;

EID: 84889080811     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-013-1428-y     Document Type: Article

References (39)

1. Horning SJ, Rosenberg SA (1984) The natural history of initially untreated low-grade non-Hodgkin lymphomas. N Engl J Med 311:1471-1475
2. Oka T, Ouchida M, Koyama M, Ogama Y, Takada S, Nakatani Y, Tanaka T, Yoshino T, Hayashi K, Ohara N, Kondo E, Takahashi K, Tsuchiyama J, Tanimoto M, Shimizu K, Akagi T (2002) Gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias/lymphomas. Cancer Res 62:6390-6394
3. Shaknovich R, Melnick A (2011) Epigenetics and B-cell lymphoma. Curr Opin Hematol 18:293-299
4. Lessard J, Schumacher A, Sauvageau G (1998) Stage-specific expression of polycomb group genes in human bone marrow cells. Blood 91:1216-1224
5. Sauvageau M, Sauvageau G (2010) Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Stem Cell 7:299-313
6. Gao Z, Zhang J, Bonasio R, Strino F, Sawai A, Parisi F, Kluger Y, Reinberg D (2012) PCGF homologs, CBX proteins, and RYBP define functionally distinct PRC1 family complexes. Mol Cell 45:344-356
7. Cao R, Wang L, Wang H, Erdjument-Bromage H, Tempst P, Jones RS, Zhang Y (2002) Role of histone H3 lysine 27 methylation in polycomb-group silencing. Science 298:1039-1043
8. Czermin B, Melfi R, McCabe D, Seitz V, Imhof A, Pirrotta V (2002) Drosophila enhancer of zeste/ESC complexes have a histone H3 methyltransferase activity that marks chromosomal Polycomb sites. Cell 111:185-196
9. Shao Z, Raible F, Mollaaghababa R, Guyon JR, Wu CT, Bender W, Kingston RE (1999) Stabilization of chromatin structure by PRC1, a polycomb complex. Cell 98:37-46
10. Wang L, Brown JL, Cao R, Zhang Y, Kassis JA, Jones RS (2004) Hierarchical recruitment of polycomb group silencing complexes. Mol Cell 14:637-646
11. Arf senescence pathways. Genes Dev 19:1432-1437
12. Cui H, Hu B, Li T, Ma J, Alam G, Gunning WT, Ding HF (2007) BMI-1 is essential for the tumourigenicity of neuroblastoma cells. Am J Pathol 170:1370-1378
13. Haupt Y, Bath ML, Harris AW, Adams JM (1993) bmi-1 transgene induces lymphomas and collaborates with myc in tumourigenesis. Oncogene 8:3161-3164
14. Van Galen JC, Muris JJ, Oudejans JJ, Vos W, Giroth CP, Ossenkoppele GJ, Otte AP, Raaphorst FM, Meijer CJ (2007) Expression of the polycomb-group gene BMI-1 is related to an unfavorable prognosis in primary nodal DLBCL. J Clin Pathol 60:167-172
15. Wang W, Yuasa T, Tsuchiya N, Ma Z, Maita S, Narita S, Kumazawa T, Inoue T, Tsuruta H, Horikawa Y, Saito M, Hu W, Ogawa O, Habuchi T (2009) The novel tumor-suppressor Mel-18 in prostate cancer: its functional polymorphism, expression and clinical significance. Int J Cancer 125:2836-2843
16. Zhang XW, Sheng YP, Li Q, Qin W, Lu YW, Cheng YF, Liu BY, Zhang FC, Li J, Dimri GP, Guo WJ (2010) BMI1 and Mel-18 oppositely regulate carcinogenesis and progression of gastric cancer. Mol Cancer 9:40
17. Riis ML, Lüders T, Nesbakken AJ, Vollan HS, Kristensen V, Bukholm IR (2010) Expression of BMI-1 and Mel-18 in breast tissue - a diagnostic marker in patients with breast cancer. BMC Cancer 10:686
18. Dimri M, Bommi PV, Sahasrabuddhe AA, Khandekar JD, Dimri GP (2010) Dietary omega-3 polyunsaturated fatty acids suppress expression of EZH2 in breast cancer cells. Carcinogenesis 31:489-495
19. Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, Haukaas SA, Salvesen HB, Otte AP, Akslen LA (2006) EZH2 expression is associated with high proliferation rate and aggressive tumour subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 24:268-273
20. Wang CG, Ye YJ, Yuan J, Liu FF, Zhang H, Wang S (2010) EZH2 and STAT6 expression profiles are correlated with colorectal cancer stage and prognosis. World J Gastroenterol 16:2421-2427
21. Morin RD, Johnson NA, Severson TM et al (2010) Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-centre origin. Nat Genetics 42:181-185
22. Yap DB, Chu J, Berg T, Schapira M, Cheng SW, Moradian A, Morin RD, Mungall AJ, Meissner B, Boyle M, Marquez VE, Marra MA, Gascoyne RD, Aparicio SA (2010) Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 117:2451-2459
23. Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, Jones AV, Waghorn K, Zoi K, Ross FM, Reiter A, Hochhaus A, Drexler HG, Duncombe A, Cervantes F, Oscier D, Boultwood J, Grand FH, Cross NC (2010) Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 42:722-726
24. Swerdlow SH, Campo E, Harris NL et al (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. IARC, Lyon
25. Hans CP, Weisenburger DD, Greiner TC et al (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275-282
26. Hamer KM, Sewalt RG, den Blaauwen JL, Hendrix T, Satijn DP, Otte AP (2002) A panel of monoclonal antibodies against human polycomb group proteins. Hybrid Hybridomics 21:245-252
27. Sewalt RG, van der Vlag J, Gunster MJ, Hamer KM, den Blaauwen JL, Satijn DP, Hendrix T, van Driel R, Otte AP (1998) Characterization of interactions between the mammalian polycomb-group proteins Enx1/EZH2 and EED suggests the existence of different mammalian polycomb-group protein complexes. Mol Cell Biol 18:3586-3595
28. Oka T, Yoshino T, Hayashi K, Ohara N, Nakanishi T, Yamaai Y, Hiraki A, Aoki-Sogawa C, Kondo E, Teramoto N, Takahashi K, Tsuchiyama J, Akagi T (2001) Reduction of hematopoietic cell-specific tyrosine phosphatase SHP-1 gene expression in natural killer cell lymphoma and various types of lymphomas/leukemias: combination analysis with cDNA expression array and tissue microarray. Am J Pathol 159:1495-1505
29. Raaphorst FM, Otte AP, van Kemenade FJ, Blokzijl T, Fieret E, Hamer KM, Satijn DP, Meijer CJ (2001) Distinct BMI-1 and EZH2 expression patterns in thymocytes and mature T cells suggest a role for polycomb genes in human T cell differentiation. J Immunol 166:5925-5934
30. Raaphorst FM, van Kemenade FJ, Fieret JH, Satijn DPE, Otto AP, Meijer CJ (2000) Cutting edge: polycomb gene expression patterns reflect distinct B-cell differentiation stages in human germinal centres. J Immunol 164:1-4
31. Lessard J, Schumacher A, Thorsteinsdottir U, van Lohuizen M, Magnuson T, Sauvageau G (1999) Functional antagonism of the polycomb-group genes eed and Bmi-1 in hemopoietic cell proliferation. Genes Dev 13:2691-2703
32. Van Lohuizen M (1999) The trithorax groups and Polycomb group chromatin modifiers: implications for disease. Curr Opin Genet Dev 9:355-361
33. Van Galen JC, Dukers DF, Giroth C, Sewalt RG, Otte AP, Meijer CJ, Raaphorst FM (2004) Distinct expression patterns of polycomb oncoproteins and their binding partners during the germinal center reaction. Eur J Immunol 34:1870-1881
34. Van Kemenade FJ, Raaphorst FM, Blokzijl T, Fieret E, Hamer KM, Satijn DP, Otte AP, Meijer CJ (2001) Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. Blood 97:3896-3901
35. Alizadeh AA, Eisen MB, Davis RE et al (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503-511
36. Jacobs JJ, Scheijen B, Voncken JW, Kieboom K, Berns AJM, van Lohuizen M (1999) Bmi-1 collaborates with c-Myc in tumourigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes De 13:2678-2690
37. Schoeftner S, Sengupta AK, Kubicek S, Mechtler K, Spahn L, Koseki H, Jenuwein T, Wutz A (2006) Recruitment of PRC1 function at the initiation of X inactivation independent of PRC2 and silencing. EMBO J 25:3110-3122
38. Sing A, Pannell D, Karaiskakis A, Sturgeon K, Djabali M, Ellis J, Lipshitz HD, Cordes SP (2009) A vertebrate polycomb response element governs segmentation of the posterior hindbrain. Cell 138:885-897
39. McCabe MT, Ott HM, Ganji G et al (2012) EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492:108-112